{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:39:39Z","timestamp":1776109179420,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clinthera.2020.09.002","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T02:08:03Z","timestamp":1604369283000},"page":"2171-2183.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug\u2013Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers"],"prefix":"10.1016","volume":"42","author":[{"given":"Tadakatsu","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.09.002_bib1","doi-asserted-by":"crossref","first-page":"1204598","DOI":"10.1155\/2018\/1204598","article-title":"Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology","volume":"2018","author":"Cannavo","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.clinthera.2020.09.002_bib2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.HYP.0000172622.51973.f5","article-title":"Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation","volume":"46","author":"Ishizawa","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.09.002_bib3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.09.002_bib4","first-page":"37","article-title":"New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure","volume":"33","author":"Capelli","year":"2020","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.clinthera.2020.09.002_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MNH.0000000000000340","article-title":"Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease","volume":"26","author":"Dojki","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.clinthera.2020.09.002_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.09.002_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","article-title":"Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts","volume":"46","author":"Nagai","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.09.002_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.steroids.2014.05.001","article-title":"Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome","volume":"91","author":"Marzolla","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.clinthera.2020.09.002_bib9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","article-title":"Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet","volume":"151","author":"Wada","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2020.09.002_bib10","doi-asserted-by":"crossref","first-page":"E1415","DOI":"10.1152\/ajpendo.00419.2013","article-title":"Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet","volume":"305","author":"Wada","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2020.09.002_bib11","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/liv.12794","article-title":"Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis","volume":"35","author":"Pizarro","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2020.09.002_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-020-1023-y","article-title":"Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists","volume":"22","author":"Sueta","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.clinthera.2020.09.002_bib13","article-title":"Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers","author":"Nakamura","year":"2020","journal-title":"Clin Pharmacol Drug Develop"},{"key":"10.1016\/j.clinthera.2020.09.002_bib14","first-page":"443","article-title":"The conduct of in\u00a0vitro and in\u00a0vivo drug-drug interaction studies: a PhRMA perspective","volume":"43","author":"Bjornsson","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.09.002_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0091270007310382","article-title":"Lack of a pharmacokinetic effect of raltegravir on midazolam: in\u00a0vitro\/in\u00a0vivo correlation","volume":"48","author":"Iwamoto","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.09.002_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0091270004264164","article-title":"Absence of a pharmacokinetic interaction between etanercept and warfarin","volume":"44","author":"Zhou","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.09.002_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12325-009-0003-z","article-title":"Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist","volume":"26","author":"Denker","year":"2009","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2020.09.002_bib18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1124\/dmd.30.12.1344","article-title":"Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5","volume":"30","author":"Cook","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2020.09.002_bib19","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/bcp.14302","article-title":"Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects","volume":"86","author":"Kirigaya","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.09.002_bib20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:33Z","timestamp":1758963153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820304264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0149291820304264"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.09.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug\u2013Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}